<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03832049</url>
  </required_header>
  <id_info>
    <org_study_id>SCC 1597</org_study_id>
    <nct_id>NCT03832049</nct_id>
  </id_info>
  <brief_title>HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial</brief_title>
  <acronym>HPV</acronym>
  <official_title>A Randomized, Observer-blind, Non-inferiority Trial to Evaluate Alternative Human Papillomavirus (HPV) Vaccination Schedules in Females in West Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, observer-blind non-inferiority trial to evaluate alternative human&#xD;
      papillomavirus (HPV) vaccination schedules in young females in West Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, single-centre, phase 3 non-inferiority clinical trial&#xD;
      of the Gardasil 9 vaccine. It will be undertaken in three female cohorts (15 to 26 years old;&#xD;
      9 to 14 years-olds and 4 to 8 year-olds). In total 1720 female participants will be recruited&#xD;
      in a rural setting in The Gambia, West Africa.&#xD;
&#xD;
      The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6,&#xD;
      11,16,18,31,33,45,52 and 58 VLP. It is licensed by both European Medicines Agency and the US&#xD;
      Food and Drug Administration as a two or three dose schedule to 9 to 14 year olds and as a&#xD;
      three dose schedule to 15 to 26 years olds. The license covers both males and females. The&#xD;
      vaccine is not currently licensed for those under 9 years of age and it is not licenced in&#xD;
      The Gambia.&#xD;
&#xD;
      All females within the 15 to 26 year-old cohort will receive three doses of Gardasil 9 at 0,&#xD;
      2 and 6 months and represent the reference group for the purposes of the serological&#xD;
      non-inferiority analysis. This is the only group for which efficacy data for the vaccine are&#xD;
      available. Females in the 9 to 14 year old and 4 to 8 year old cohorts will be randomized to&#xD;
      receive either one or two doses of Gardasil 9. In both groups, the two doses will be&#xD;
      administered at 0 and 6 months.&#xD;
&#xD;
      The primary and secondary immunogenicity objectives will be analysed based on serological&#xD;
      Samples taken 4 to 6 weeks after the last dose of vaccine received according to group.&#xD;
      Additional analysis will be undertaken at 12, 24 and 36 months. The Sampling schedule is&#xD;
      aligned with the schedule in other immunogenicity trials to facilitate comparison and&#xD;
      potential immunobridging to future one-dose efficacy data. In addition, the stability of the&#xD;
      antibody concentrations between 12 and 24 and again between 24 and 36 months according to&#xD;
      schedule and age-group aims to allow longer term predictions regarding the maintenance of&#xD;
      antibody concentration to be made.&#xD;
&#xD;
      A Sub-study will be undertaken within the main trial to compare in detail early immunological&#xD;
      events taking place following Gardasil 9. The quantitative and qualitative changes in these&#xD;
      events following a first and following subsequent doses of the vaccine and also according to&#xD;
      age will be assessed and related to the early and long-term antibody concentrations induced&#xD;
      by the vaccine. There are currently no data exploring the basis for the progressive increase&#xD;
      in the immunogenicity of the HPV vaccines apparent with decreasing age. These may have their&#xD;
      origins in the early innate response following vaccination-which will be assessed at a&#xD;
      cellular as well as transcriptomic level, as well as in the subsequent adaptive profile.&#xD;
&#xD;
      Similarly, the cellular basis for the sustained seropositivity induced by the HPV vaccines&#xD;
      even apparent following a single vaccine dose is little understood. The window onto which&#xD;
      plasmablasts and memory B-cell populations in the circulation is transient following&#xD;
      vaccination. However, enumerating and characterizing these populations and relating them in&#xD;
      the same way to early and long term antibody concentration aims to provide insight into the&#xD;
      relative roles of these populations and how they are influenced by the age of the vaccine and&#xD;
      the number of vaccine doses received.&#xD;
&#xD;
      Individuals in the sub-study will contribute serological data to the main trial and will be&#xD;
      followed up in the same way but will be consented for one additional blood sample after each&#xD;
      vaccination. Up to 120 participant in each group in the main trial will be randomized to&#xD;
      groups A, B or C, with 40 participants in each of these groups. This number aims to generate&#xD;
      a dataset of at least 30 analyzable individuals per schedule and age group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 14, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized, open-label, single-centre, phase 3, noninferiority clinical trial of the Gardasil 9 vaccine</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibodies measured by 9-valent HPV competitive Luminex immunoassay (cLIA) (mMU/mL)</measure>
    <time_frame>4 weeks after last vaccine dose</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute allergic reaction (Grade 0 - 4)</measure>
    <time_frame>Day of vaccination (day 0)</time_frame>
    <description>Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site pain (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site redness (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site swelling (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site pruritus (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature in degrees Centigrade</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nausea/vomiting (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headaches (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dizziness (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myalgia/arthralgia (Grade 0 - 4)</measure>
    <time_frame>Days 0 to 6 after vaccination</time_frame>
    <description>Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse event (AE) including serious adverse events</measure>
    <time_frame>Day 0 to day 28 following each vaccination</time_frame>
    <description>Unsolicited AE will be recorded in 4 to 8 years olds and 9 to 14 year olds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suspected unexpected serious adverse reactions (SUSAR)</measure>
    <time_frame>Day 0 to month 36</time_frame>
    <description>SUSAR will be collected from all participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibodies measured by 9-valent HPV cLIA (mMU/mL)</measure>
    <time_frame>12 months after first vaccination</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies measured by 9-valent HPV cLIA (mMU/mL)</measure>
    <time_frame>24 months after first vaccination</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies measured by 9-valent HPV cLIA (mMU/mL)</measure>
    <time_frame>36 months after first vaccination</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies measure by 9-valent HPV total IgG (TIgG)</measure>
    <time_frame>4 weeks after last vaccine dose</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies measure by 9-valent HPV TIgG</measure>
    <time_frame>12 months after first vaccination</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies measure by 9-valent HPV TIgG</measure>
    <time_frame>24 months after first vaccination</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies measure by 9-valent HPV TIgG</measure>
    <time_frame>36 months after first vaccination</time_frame>
    <description>HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1720</enrollment>
  <condition>Human Papillomavirus Vaccine</condition>
  <arm_group>
    <arm_group_label>15 to 26 years - 3 dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 to 14 years - 2 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 to 8 years - 2 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 to 14 years - 1 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 to 8 years - 1 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses</intervention_name>
    <description>0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)</description>
    <arm_group_label>15 to 26 years - 3 dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses</intervention_name>
    <description>0.5mL intramuscular dose - 2 doses (0 and 6 months)</description>
    <arm_group_label>4 to 8 years - 2 dose</arm_group_label>
    <arm_group_label>9 to 14 years - 2 dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose</intervention_name>
    <description>0.5mL intramuscular dose - 1 doses (0 months)</description>
    <arm_group_label>4 to 8 years - 1 dose</arm_group_label>
    <arm_group_label>9 to 14 years - 1 dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed/thumb-printed informed consent obtained from the participant's parent (4 to 17&#xD;
             year-olds) or signed/thumb-printed informed consent obtained from the participant (18&#xD;
             years and above)&#xD;
&#xD;
          -  Signed/thumb-printed assent obtained from the participant (12 to 17 year-olds only).&#xD;
&#xD;
          -  Documented verbal assent obtained from the participant (6 to 11 year-olds only)&#xD;
&#xD;
          -  Participant is of female sex (based on participant/parent self-report)&#xD;
&#xD;
          -  Participant is between 4 and 26 years of age inclusive&#xD;
&#xD;
          -  Parent/participant is willing and judged able to comply with the necessary study&#xD;
             procedures&#xD;
&#xD;
          -  Parent/participant does not have established plans to leave the study area for a&#xD;
             prolonged period/indefinitely during the 3 year follow-up period&#xD;
&#xD;
          -  Participant is resident within the study area (no fixed boundaries will be set and&#xD;
             decisions will be made on a case-by-case basis by the study team taking into account&#xD;
             not only distance but also transport links, accessibility for the purposes of safety&#xD;
             data collection, willingness of the parent/participant to travel)&#xD;
&#xD;
          -  Place of residence of the participant must be readily identifiable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of other investigational medicinal products (IMP) in a period of 12 months&#xD;
             prior to the day of randomization and vaccination or plans to receive IMP during the&#xD;
             trial.&#xD;
&#xD;
          -  Presence of significant chronic health problems requiring long-term medication or&#xD;
             medical follow-up including respiratory, cardiac, gastrointestinal, hepatic, renal,&#xD;
             neurological, musculoskeletal, haematological or other conditions based on parental&#xD;
             history and physical examination of the participant. Participants with known sickle&#xD;
             cell disease (but not sickle cell trait) will be excluded.&#xD;
&#xD;
          -  History of severe allergic reactions to any prior vaccine or to any component of the&#xD;
             study vaccine (including alum (amorphous aluminum hydroxyphosphate sulphate), yeast or&#xD;
             Benzonase). Severe allergic reactions are defined as reactions requiring urgent&#xD;
             medical intervention including reactions with any degree of cardiorespiratory&#xD;
             compromise. The occurrence of a mild rash without other associated symptoms or signs&#xD;
             does not generally represent an exclusion. Allergic reactions should be distinguished&#xD;
             from the local and systemic reactogenicity expected in the first few days following&#xD;
             vaccination which is not an exclusion to vaccination&#xD;
&#xD;
          -  Prior receipt of an HPV vaccine&#xD;
&#xD;
          -  Receipt of any vaccine in the 28 days prior to randomization and vaccination‡&#xD;
&#xD;
          -  History of thrombocytopenia or coagulation disorders which represent contraindications&#xD;
             in intramuscular (IM) vaccination&#xD;
&#xD;
          -  Known congenital or acquired immune deficiency or history strongly indicative of&#xD;
             abnormal immune function. HIV testing will not be undertaken as part of the routine&#xD;
             screening procedures due to the relatively low prevalence of HIV expected in the&#xD;
             population (~1-3%) and the established safety and immunogenicity profile of Gardasil&#xD;
             in HIV positive individuals.&#xD;
&#xD;
          -  Receipt of medications or other treatments known to suppress the immune system in a&#xD;
             period of 12 months prior to the day of randomization or plans to receive such&#xD;
             medications and treatments during the course of the trial. Such medications and&#xD;
             treatments include but not limited to high dose non-replacement) oral or parenteral&#xD;
             steroids for more than 14 days, chemotherapeutic agents, methotrexate,&#xD;
             cyclophosphamide, cyclosporin, Tacrolimus, any monoclonal antibody therapy and&#xD;
             radiotherapy. The use of topical and inhaled steroids are not exclusion criteria.&#xD;
&#xD;
          -  Receipt of intravenous immunoglobulins or blood products within a period of 12 months&#xD;
             prior to the day of randomization and vaccination or plans to receive such products&#xD;
             during the course of the trial.&#xD;
&#xD;
          -  Pregnancy (females in the 15 to 26 years old cohort will require a urine pregnancy&#xD;
             test as part of the screening procedures and will also have a urine pregnancy test&#xD;
             undertaken prior to the second and third vaccination and vaccination delayed if&#xD;
             pregnancy is confirmed. A minimum of 42 days from the end of pregnancy (irrespective&#xD;
             of outcome) will be left before the delayed vaccination is administered. Participants&#xD;
             who are pregnant at initial screening will not be re-screened but will be defined as&#xD;
             screen failures. Breast feeding is not an exclusion criterion&#xD;
&#xD;
          -  Intention to become pregnant within six months of enrollment in the trial.&#xD;
             Confirmation regarding the use of a reliable method of contraception is not required&#xD;
             but females who are actively seeking to become pregnant within six months of&#xD;
             enrollment will be excluded.&#xD;
&#xD;
          -  Fever (&gt;38.0°C) on the day of vaccination or documented fever (&gt;38.0°C) within the 24&#xD;
             hours preceding vaccination&#xD;
&#xD;
          -  Abnormal (Grade &gt; 1) vital signs (heart rate, respiratory rate, blood pressure) on the&#xD;
             day of vaccination&#xD;
&#xD;
          -  Positive rapid diagnostic test (RDT) or blood film for malaria on the day of&#xD;
             vaccination&#xD;
&#xD;
          -  Clinically-significant (Grade &gt; 2) acute illness present on the day of vaccination&#xD;
             (minor illnesses including upper respiratory tract infections, diarrhoeal illness and&#xD;
             skin complaints not associated with fever or significant systemic upset are not in&#xD;
             themselves reasons for exclusion)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participant is of female sex (based on participant/parent self-report)</gender_description>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ed Clarke, MB ChB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Council @ LSHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ed Clarke</name>
      <address>
        <city>Banjul</city>
        <state>Outside U.S. And Canada</state>
        <zip>PO Box 273</zip>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gambia</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>March 15, 2022</last_update_submitted>
  <last_update_submitted_qc>March 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccination in healthy females</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03832049
org study id: SCC 1597
nct id: NCT03832049
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
A randomized, observer-blind non-inferiority trial to evaluate alternative human
      papillomavirus (HPV) vaccination schedules in young females in West Africa.
This study is a randomized, open-label, single-centre, phase 3 non-inferiority clinical trial
      of the Gardasil 9 vaccine. It will be undertaken in three female cohorts (15 to 26 years old;
      9 to 14 years-olds and 4 to 8 year-olds). In total 1720 female participants will be recruited
      in a rural setting in The Gambia, West Africa.

      The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6,
      11,16,18,31,33,45,52 and 58 VLP. It is licensed by both European Medicines Agency and the US
      Food and Drug Administration as a two or three dose schedule to 9 to 14 year olds and as a
      three dose schedule to 15 to 26 years olds. The license covers both males and females. The
      vaccine is not currently licensed for those under 9 years of age and it is not licenced in
      The Gambia.

      All females within the 15 to 26 year-old cohort will receive three doses of Gardasil 9 at 0,
      2 and 6 months and represent the reference group for the purposes of the serological
      non-inferiority analysis. This is the only group for which efficacy data for the vaccine are
      available. Females in the 9 to 14 year old and 4 to 8 year old cohorts will be randomized to
      receive either one or two doses of Gardasil 9. In both groups, the two doses will be
      administered at 0 and 6 months.

      The primary and secondary immunogenicity objectives will be analysed based on serological
      Samples taken 4 to 6 weeks after the last dose of vaccine received according to group.
      Additional analysis will be undertaken at 12, 24 and 36 months. The Sampling schedule is
      aligned with the schedule in other immunogenicity trials to facilitate comparison and
      potential immunobridging to future one-dose efficacy data. In addition, the stability of the
      antibody concentrations between 12 and 24 and again between 24 and 36 months according to
      schedule and age-group aims to allow longer term predictions regarding the maintenance of
      antibody concentration to be made.

      A Sub-study will be undertaken within the main trial to compare in detail early immunological
      events taking place following Gardasil 9. The quantitative and qualitative changes in these
      events following a first and following subsequent doses of the vaccine and also according to
      age will be assessed and related to the early and long-term antibody concentrations induced
      by the vaccine. There are currently no data exploring the basis for the progressive increase
      in the immunogenicity of the HPV vaccines apparent with decreasing age. These may have their
      origins in the early innate response following vaccination-which will be assessed at a
      cellular as well as transcriptomic level, as well as in the subsequent adaptive profile.

      Similarly, the cellular basis for the sustained seropositivity induced by the HPV vaccines
      even apparent following a single vaccine dose is little understood. The window onto which
      plasmablasts and memory B-cell populations in the circulation is transient following
      vaccination. However, enumerating and characterizing these populations and relating them in
      the same way to early and long term antibody concentration aims to provide insight into the
      relative roles of these populations and how they are influenced by the age of the vaccine and
      the number of vaccine doses received.

      Individuals in the sub-study will contribute serological data to the main trial and will be
      followed up in the same way but will be consented for one additional blood sample after each
      vaccination. Up to 120 participant in each group in the main trial will be randomized to
      groups A, B or C, with 40 participants in each of these groups. This number aims to generate
      a dataset of at least 30 analyzable individuals per schedule and age group.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: a randomized, open-label, single-centre, phase 3, noninferiority clinical trial of the Gardasil 9 vaccine
primary purpose: Prevention
masking: Single (Outcomes Assessor)
measure: Antibodies measured by 9-valent HPV competitive Luminex immunoassay (cLIA) (mMU/mL)
time frame: 4 weeks after last vaccine dose
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Acute allergic reaction (Grade 0 - 4)
time frame: Day of vaccination (day 0)
description: Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Injection site pain (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Injection site redness (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Injection site swelling (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Injection site pruritus (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited local reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Temperature in degrees Centigrade
time frame: Days 0 to 6 after vaccination
description: Recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Nausea/vomiting (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Headaches (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Dizziness (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Fatigue (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Myalgia/arthralgia (Grade 0 - 4)
time frame: Days 0 to 6 after vaccination
description: Solicited systemic reactogenicity recorded in 4 to 8 year olds and 9 to 14 year olds
measure: Unsolicited adverse event (AE) including serious adverse events
time frame: Day 0 to day 28 following each vaccination
description: Unsolicited AE will be recorded in 4 to 8 years olds and 9 to 14 year olds
measure: Suspected unexpected serious adverse reactions (SUSAR)
time frame: Day 0 to month 36
description: SUSAR will be collected from all participants
measure: Antibodies measured by 9-valent HPV cLIA (mMU/mL)
time frame: 12 months after first vaccination
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Antibodies measured by 9-valent HPV cLIA (mMU/mL)
time frame: 24 months after first vaccination
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Antibodies measured by 9-valent HPV cLIA (mMU/mL)
time frame: 36 months after first vaccination
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Antibodies measure by 9-valent HPV total IgG (TIgG)
time frame: 4 weeks after last vaccine dose
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Antibodies measure by 9-valent HPV TIgG
time frame: 12 months after first vaccination
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Antibodies measure by 9-valent HPV TIgG
time frame: 24 months after first vaccination
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
measure: Antibodies measure by 9-valent HPV TIgG
time frame: 36 months after first vaccination
description: HPV types, 6, 11, 16, 18, 31, 33, 45, 52 and 58
arm group label: 15 to 26 years - 3 dose
arm group type: Active Comparator
description: 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
arm group label: 9 to 14 years - 2 dose
arm group type: Experimental
description: 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
arm group label: 4 to 8 years - 2 dose
arm group type: Experimental
description: 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
arm group label: 9 to 14 years - 1 dose
arm group type: Experimental
description: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
arm group label: 4 to 8 years - 1 dose
arm group type: Experimental
description: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
intervention type: Biological
intervention name: 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
description: 0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
arm group label: 15 to 26 years - 3 dose
intervention type: Biological
intervention name: 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
description: 0.5mL intramuscular dose - 2 doses (0 and 6 months)
arm group label: 4 to 8 years - 2 dose
arm group label: 9 to 14 years - 2 dose
intervention type: Biological
intervention name: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
description: 0.5mL intramuscular dose - 1 doses (0 months)
arm group label: 4 to 8 years - 1 dose
arm group label: 9 to 14 years - 1 dose
criteria: 
gender: Female
gender based: Yes
gender description: Participant is of female sex (based on participant/parent self-report)
minimum age: 4 Years
maximum age: 26 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Ed Clarke, MB ChB PhD
role: Principal Investigator
affiliation: Medical Research Council @ LSHTM
facility: 
country: Gambia
responsible party type: Sponsor
mesh term: Vaccines